Legal & General Group Plc grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 30.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,223 shares of the company's stock after purchasing an additional 36,949 shares during the quarter. Legal & General Group Plc owned approximately 0.08% of Cellebrite DI worth $3,530,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. State Street Corp raised its holdings in shares of Cellebrite DI by 7.3% in the third quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after purchasing an additional 30,052 shares during the last quarter. Barclays PLC lifted its position in shares of Cellebrite DI by 29.1% during the 3rd quarter. Barclays PLC now owns 263,657 shares of the company's stock worth $4,439,000 after buying an additional 59,395 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Cellebrite DI by 59.3% in the 3rd quarter. Tidal Investments LLC now owns 104,478 shares of the company's stock worth $1,759,000 after buying an additional 38,887 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Cellebrite DI in the third quarter valued at approximately $11,523,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI during the third quarter valued at approximately $23,402,000. 45.88% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have issued reports on CLBT. Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has an average rating of "Buy" and an average target price of $23.43.
Read Our Latest Stock Report on CLBT
Cellebrite DI Trading Up 1.1 %
Shares of CLBT stock opened at $18.39 on Wednesday. The firm's 50 day moving average is $18.79 and its 200 day moving average is $20.10. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock has a market capitalization of $4.40 billion, a P/E ratio of -13.23, a PEG ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
